All News

Coverage denials delay care, drive patients into debt, and erode trust in insurers—yet nearly half of affected patients never appeal.

Longer-term data support pimicotinib as an effective, well-tolerated option for a rare benign tumor that can cause significant joint disability.

Surgical therapy for diabetic gastroparesis was associated with meaningful reductions in HbA1c and lower rates of diabetes-related complications.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

GLP-1s, care standards updates, nutritional guidance, and AI adoption in diabetes management are just a few of the hot topics to be presented and debated.

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.

A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF.

The fluocinolone acetonide intravitreal implant showed durable improvements in anatomical and functional outcomes over a follow-up period of 36 months.

Heat-attributable CVD burden could reach 418 DALYs per 100,000 by 2050 under high-emissions scenarios, with low-income counties hit hardest.

Manufacturing questions delay review of dexmethylphenidate candidate; no safety or efficacy concerns raised.

The update makes biologics first-line treatment, adds comorbidity management guidance, and aligns practice with evolving European guidelines for psoriasis.

Most patients achieved stable or reduced lesion burden and the treatment was well tolerated by patients.

James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.

Trauma after cancer is underdiagnosed and often persists into survivorship, with experts urging trauma-informed screening in oncology care.

As quarantined cruise passengers return home, experts explain Andes hantavirus symptoms, transmission risks, and prevention.

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

New CMS Medicaid work requirements could increase employment but may also cause millions of adults to lose coverage by 2027.

Real-world data suggest nirogacestat boosts response in desmoid tumor vs standard-of-care treatment, but small cohorts leave key outcomes unanswered.

Medicare’s GLP-1 Bridge offers temporary coverage for obesity medication at $50/month, but patients face a 2027 cliff as BALANCE stalls.

Abortion costs and Medicaid coverage vary by state, creating financial barriers for patients seeking care after the Dobbs v Jackson decision.

Accountable care offers one of the most promising frameworks for stabilizing and expanding access, but only if policy is intentionally designed to support rural participation.

Data presented at ASCO support wider use of prophylactic therapy to prevent cytokine release syndrome as efforts expand to promote bispecifics in treatment of multiple myeloma.

Girls and young women, as well as older teens, were more likely to report AI chatbot use for mental health advice, with Black youth more likely to engage monthly.

Data confirm the use of daratumumab, bortezomib, lenalidomide, and dexamethasone as the standard of care in newly diagnosed multiple myeloma.

Children aged 2 to 5 years with fall birthdays had higher flu vaccination rates and fewer diagnoses than those with summer birthdays.

FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms.

Asthma and Allergy Awareness Month shines light on the ways that asthma can affect long-term health.

Phase 3 trials show bepirovirsen delivers ~20% functional cure in chronic hepatitis B in just 24 weeks.